Pacific Shuanglin Bio-pharmacy Co (000403.SZ) Stock Price
Pacific Shuanglin Bio-pharmacy Co Price
Over the last 19 years Pacific Shuanglin Bio-pharmacy Co grew revenue by 7.4% annually, reaching 2.63 B CNY. Earnings per share have grown at 10.1% per year over the last 18 years. For Pacific Shuanglin Bio-pharmacy Co, the net margin of 15.9% is down versus 19.8% a few years ago. At today's price the dividend yield works out to roughly 2.85%. The payout ratio is around 61% of earnings. The dividend has grown at 23.8% per year over the past 5 years. The consensus 12-month price target for Pacific Shuanglin Bio-pharmacy Co is 21.86 CNY, about 131.3% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.
Pacific Shuanglin Bio-pharmacy Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Pacific Shuanglin Bio-pharmacy Co business model & stock analysis
Frequently asked questions about Pacific Shuanglin Bio-pharmacy Co
Analysts currently set an average price target of 21.24 CNY for the Pacific Shuanglin Bio-pharmacy Co stock (median: 21.86 CNY), implying +124.8 % versus the latest price. The consensus is based on 8 analyst ratings.
Pacific Shuanglin Bio-pharmacy Co Analyst Price Targets 2026
8 analysts currently rate the Pacific Shuanglin Bio-pharmacy Co stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Pacific Shuanglin Bio-pharmacy Co to generate revenue of 2.37 B CNY and earnings per share of 0.33 CNY.
Pacific Shuanglin Bio-pharmacy Co Analyst Price Targets 2026
Converted at the current exchange rate, the Pacific Shuanglin Bio-pharmacy Co share trades at 1.27 EUR (9.45 CNY).
The Pacific Shuanglin Bio-pharmacy Co share (000403.SZ) is listed on 1 stock exchanges, including: Shenzhen (000403.SZ).
The expected revenue of Pacific Shuanglin Bio-pharmacy Co is 2.37 B CNY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Pacific Shuanglin Bio-pharmacy Co is 313.63 M CNY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Pacific Shuanglin Bio-pharmacy Co is currently 28.64. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pacific Shuanglin Bio-pharmacy Co stock.
The price-to-sales ratio (P/S) of Pacific Shuanglin Bio-pharmacy Co is currently 3.79. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pacific Shuanglin Bio-pharmacy Co stock.
The Eulerpool Quality Score for Pacific Shuanglin Bio-pharmacy Co is 5/10.
The ISIN of Pacific Shuanglin Bio-pharmacy Co is CNE000000F14. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Pacific Shuanglin Bio-pharmacy Co is 000403.SZ. The ticker symbol is used to trade Pacific Shuanglin Bio-pharmacy Co shares on the stock exchange.
Pacific Shuanglin Bio-pharmacy Co stock
Pacific Shuanglin Bio-pharmacy Co Peer Group
Pacific Shuanglin Bio-pharmacy Co Ticker
Pacific Shuanglin Bio-pharmacy Co FIGI
All fundamentals and in-depth analysis of Pacific Shuanglin Bio-pharmacy Co
Our stock analysis for Pacific Shuanglin Bio-pharmacy Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pacific Shuanglin Bio-pharmacy Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.